Related Experiment Video
Updated: Aug 23, 2025
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Deciphering the enigma of neuroendocrine prostate cancer
Abstract:
Despite the clinical advances in managing metastatic prostate cancer in the last 20 years, treatments for patients with metastatic disease only offer a brief respite from disease progression, especially after first-line therapies. Research into treatment resistance has defined a subset of patients with neuroendocrine differentiation of their prostate adenocarcinoma. Although neuroendocrine findings in conjunction with prostate adenocarcinoma can be seen in pathology samples at all stages of disease, the neuroendocrine variant of prostate cancer associated with poor outcomes occurs in approximately 20% of men with advanced disease. In this issue of JCI, Zhao, Sperger, and colleagues present data for a promising biomarker platform that can detect neuroendocrine prostate cancer after serial sampling of patients' blood with a high degree of sensitivity and specificity. This assay will be tested in several current and future trials to better define its potential clinical role and perhaps provide a greater understanding of neuroendocrine prostate cancer itself.
Insights
A new blood test shows promise for detecting neuroendocrine prostate cancer, a difficult-to-treat form of the disease. This biomarker platform could improve diagnosis and understanding of aggressive prostate cancer variants.
Area of Science:
- Oncology
- Biomarker Development
- Prostate Cancer Research
Background:
- Metastatic prostate cancer treatments offer limited long-term benefit, particularly after initial therapies.
- Treatment resistance in prostate cancer is linked to neuroendocrine differentiation.
- Neuroendocrine prostate cancer (NEPC) is associated with poor outcomes in about 20% of advanced cases.
Purpose of the Study:
- To present a novel biomarker platform for detecting neuroendocrine prostate cancer (NEPC).
- To evaluate the sensitivity and specificity of the proposed assay for NEPC detection.
Main Methods:
- Serial blood sampling from patients.
- Development and validation of a biomarker platform to detect NEPC-specific markers.
Main Results:
- The biomarker platform demonstrated high sensitivity and specificity in detecting NEPC.
- The assay allows for detection through minimally invasive serial blood sampling.
Conclusions:
- The presented biomarker platform shows significant potential for diagnosing neuroendocrine prostate cancer.
- Further clinical trials are planned to establish the role of this assay in patient management and to deepen the understanding of NEPC.
Related Concept Videos
02:17The Tumor Microenvironment
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...